SCHEMBL2861360

SCHEMBL2861360

COc1ccc(Cn2c(=O)c3c(N)n(-c4cccc(OC)c4)nc3c3ccccc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 1/20 0.50
MAPT P10636 3/20 0.47
THRB P10828 1/20 0.47
TP53 P04637 2/20 0.46
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 1/20 0.44
KMT2A Q03164 2/20 0.44
GABRA5 P31644 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
BLM P54132 1/20 0.44
POLB P06746 3/20 0.43
GAA P10253 2/20 0.43
MAPK1 P28482 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
LMNA P02545 1/20 0.42
HDAC1 Q13547 1/20 0.42
MEN1 O00255 1/20 0.42
RECQL P46063 1/20 0.42
RXFP1 Q9HBX9 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2860000 0.93 MAPT (0.49) P2RX4MAPTTHRBTP53ALDH1A1
SCHEMBL2871092 0.92 P2RX4 (0.54) P2RX4MAPTTP53ALDH1A1KDM4E
SCHEMBL2864984 0.90 RECQL (0.51) P2RX4TP53ALDH1A1SMN1; SMN2BLM
SCHEMBL2865419 0.90 HDAC1 (0.46) P2RX4MAPTTP53ALDH1A1KDM4E
SCHEMBL2870442 0.90 KMT2A (0.45) P2RX4MAPTTP53KMT2ASMN1; SMN2
SCHEMBL2866936 0.89 KMT2A (0.52) P2RX4MAPTTP53ALDH1A1KMT2A
SCHEMBL2868482 0.89 P2RX4 (0.50) P2RX4MAPTTP53ALDH1A1KMT2A
SCHEMBL2860751 0.88 P2RX4 (0.44) P2RX4MAPTTHRBTP53ALDH1A1
SCHEMBL2861651 0.87 P2RX4 (0.48) P2RX4MAPTTHRBTP53ALDH1A1
SCHEMBL2867302 0.87 P2RX4 (0.48) P2RX4MAPTTP53ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 P2RX4 718/4885MAPT 4583/4885THRB 825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.